PGP and cancer: MDR continues to pose a significant challenge in cancer therapy, displaying distinct features, such as the overexpression of the P‐glycoprotein (P‐gp) efflux pump, upregulation of anti‐apoptotic proteins, and downregulation of pro‐apoptotic proteins.